| 摘要 |
<p>A new process is claimed for the production of 131I-toluidine blue (Ia) and 125-I toluidine blue (Ib) 20mg o-toluidine blue is dissolved in 1ml distilled water by shaking 5 mins. in a vortex mixer. The solution is filtered through a 0.22 mu membrane filter into a sterile penicillin vial and the filter is rinsed with 2 x 0.5ml distilled water; 321mg KIO3 and 479mg KI are dissolved in 100ml distilled water and the solution is filtered through a 0.22 mu membrane filter, and 0.5ml of the resulting sterile KIO3/KI solution are taken up in a sterile syringe. An air cannula is inserted through the rubber stopper of the penicillin vial, 5 mCi 131I or 125I (in a volume of 0.05-0.1 ml; specific activity pref. ca 200 mCi/ml; free from reducing substances) are taken up in a sterile syringe and added to the o-toluidine blue solution, the radioactive vials being rinsed with 0.5 ml distilled water. o-Toluidine blue and radioiodine are mixed ca 30 seconds on a vortex mixer; 0.5ml KIO3/KI is added from the syringe and likewise mixed 30 seconds. 1 drop of 25% HCl is carefully added, then the air cannula is removed from the penicillin vial and the solution mixed 5 mins. on the vortex mixer. After 24-hr. incubation (when 95% plus-or-minus 2%, a pH of 7.4-7.5, and an in-vitro stability of over 4 months. (Ia) and (Ib) are useful as radiodiagnostic agents for the scintigraphy of parenchymal organs, the parathyroid and the pancreas. The new process gives (Ia) and (Ib) in high yields. The products are of high purity, stability, specific activity and radiochemical purity. The process uses small volumes of liquids.</p> |
